Back to APREView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Acute Myeloid Leukemia or Myelodysplastic Syndromes
View Full LandscapeDrug Information
Target Indication
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Clinical Trial
NCT03931291Last updated: 6/24/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
APR-246 + azacitidinePhase 3
MDS
Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 2
High-grade Serous Ovarian Cancer
ATRN-119Phase 2
Advanced Solid Tumor
Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 2
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts